Bliesath et al. demonstrated that combined inhibition of EGFR with erlotinib and CK2 with CX-4945 augmented the attenuation of Phosphatidylinositol 3-kinase (PI3K)-AKT- mammalian target of rapamycin (mTOR) signaling, antiproliferative activity, and the killing of cancer cells in in vitro as well as in vivo models of NSCLC and squamous cell carcinoma [83]. Here, EGFR is linked to non-small cell lung carcinoma.